Mar 20,2023

Electronic Skin Patches: Transforming Everyday Life, Says IDTechEx

In the report, IDTechEx investigates the technologies and applications of electronic skin patches and forecasts that the total market will grow from US$14 billion in 2023 to US$27 billion by 2033. This article delves into the exciting potential of electronic skin patches in shaping everyday life. Beyond heart rate monitoring chest straps and smartwatches, endurance athletes are exploring the use of CGMs. By continuously monitoring glucose levels, athletes can better manage their energy and optimize their performance and training to gain a competitive edge.

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 16,2023

Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Sanofi announces that it will cut the list price of Lantus (insulin glargine injection) 100 Units/mL, its most widely prescribed insulin in the U.S., by 78 percent. The company also will establish a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance, underscoring its longstanding commitment to offer affordable access to medicines.

View Analyst & Ambassador Comments
Go to original news
Mar 15,2023

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

Senseonics Holdings reported financial results for the quarter and full year ended December 31, 2022. Total revenue for the fourth quarter of 2022 was $5.6 million, compared to $4.0 million for the fourth quarter of 2021. U.S. revenue was $3.6 million in the fourth quarter of 2022, compared to $0.7 million in the prior year period, and revenue outside the U.S. was $2.0million in the fourth quarter of 2022, compared to $3.3 million in the prior year period. Total revenue for 2022 was $16.4 million compared to total revenue of $13.7 million in 2021. U.S. revenue was $7.5 million in 2022 versus $2.6 million in 2021. Revenue outside the U.S. was $8.9 million in 2022 versus $11.1 million in 2021. Global net revenue to Senseonics for the full year 2023 is expected to be in the range of $20 million to $24 million representing growth of 22% to 46% compared to 2022.

View Analyst & Ambassador Comments
Go to original news
Mar 15,2023

Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with Control-IQ Technology

Tandem Diabetes Care today announced publication of results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial by the New England Journal of Medicine showing an approximate 3-hour per day increase in time in range in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology compared to those on a standard insulin pump or multiple daily injections. All participants were using a Dexcom G6 Continuous Glucose Monitoring (CGM) System. Mean time in range with Control-IQ technology increased from 57 percent at baseline to 69 percent during follow-up compared to 55 percent to 56 percent in the control group, for a mean adjusted difference of 12.4 percent. Nighttime mean time in range was 74 percent with Control-IQ technology versus 56 percent in the control group and daytime was 67 percent versus 56 percent, respectively.

CLINICAL STUDY

#cgm

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 15,2023

Clinical Trials Finder on DigiBete

DigiBete announced on its website that the Clinical Trial Finder, in collaboration with JDRF, is ready to be used by the patients with Type1 diabetes from all ages.

View Analyst & Ambassador Comments
Go to original news
Mar 15,2023

Nemaura Medical to offer CGM-guided insulin dose titration care model

Nemaura Medical announced today that it now includes insulin under its DuoPack commercial license agreement. Loughborough, UK-based Nemaura Medical entered into a commercial agreement in September 2021 with MySugarWatch DuoPack Limited (MSWDL). Under the agreement, Nemaura’s non-invasive, wearable skin patch sensors paired with prescription-only medicines for type 2 diabetes. This created the MySugarWatch-branded “DuoPack.” The combination of sensors and medicine aimed to provide a “one-stop shop” supported by a holistic care approach. This offering used MSWDL nurses and nutritionists to create a long-term motivational relationship between patient and professional.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 14,2023

Novo Nordisk to lower pre-filled insulin device prices by up to 75%

Novo Nordisk announced today that it plans to lower U.S. prices of several insulin products by up to 75% for those with type 1 and type 2 diabetes. The price cut comes two weeks after Eli Lilly announced plans to cap out-of-pocket insulin costs at $35 with 70% price cuts. Novo Nordisk’s changes go into effect on Jan. 1, 2024.

View Analyst & Ambassador Comments
Go to original news
Mar 14,2023

GLUCOTRACK PROVIDES SHAREHOLDER UPDATE

GlucoTrack, Inc. , a medical device and digital health platform company focused on diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter. In the letter, it is metioned that the Company's vision is to become a leader in the diabetes market by providing a range of products and services addressing multiple verticals; those with Type 1 and Type 2, insulin dependent and non-insulin dependent, and prediabetes. Glucotrack's development team began Gen 2 redesign program as a project to miniaturize the Gen 1 technology into a smaller wireless ear clip that would connect to a smartphone via Bluetooth. This system utilizes ultrasound-only sensor technology, reduces the overall cost and complexity of the device, and reduces the measurement time from 60 seconds to 2 seconds.

View Analyst & Ambassador Comments
Go to original news
Mar 13,2023

Insulet to replace Silicon Valley Bank in the S&P 500

S&P Dow Jones Indices announced that Insulet is set to replace Silicon Valley Bank in the S&P 500 index. The change becomes effective prior to the opening of trading on Wednesday, March 15. It adds Insulet to the index tracking 500 large companies listed on stock exchanges in the U.S. After news of Insulet’s addition to the S&P 500, shares received a 6% boost after market hours Friday.

View Analyst & Ambassador Comments
Go to original news
Mar 09,2023

DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results

Revenues for the fourth quarter ended December 31, 2022 were $6.8 million, a 13% increase from $6.0 million for the fourth quarter ended December 31, 2021, and an increase of 3.1% from $6.6 million for the for the third quarter of 2022. The increase resulted from higher revenues from the Company's commercial (B2B) segment. Revenues for the twelve months ended December 31, 2022 were $27.7 million, a 34.8% increase from $20.5 million for the twelve months ended December 31, 2021. DarioHealth CEO Erez Raphael continued, "B2B represented approximately 59% of our total revenue in 2022, up from 4% in 2021. As our transformation to a multi-condition integrated platform continues to gain momentum in the market, we anticipate that the financial profile of the company will continue to improve driven by lower customer acquisition costs yielding gross margins of approximately 70%."

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES